This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Report highlights significant improvements in adolescent well-being in India
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Subscribe To Our Newsletter & Stay Updated
